Detail akcie Intra-Cell Thrp online

Business Summary: Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Intra-Cellular Therapies Inc revenues increased 86% to $464.4M. Net loss decreased 45% to $139.7M. Revenues reflect Grant revenue increase of 86% to $2.2M. Lower net loss reflects Biopharmaceutical segment loss decrease of 40% to $159.4M. Basic Earnings per Share excluding Extraordinary Items increased from -$2.72 to -$1.46.